Lupin completed acquisition of GAVIS Pharma

Posted on:10 Mar 2016 14:06:22
Lupin completed acquisition of GAVIS Pharma
10 March 2016 Current Affairs: Drug major Lupin Announced completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS). Lupin had announced the acquisition on July 23, 2015. GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement its Florida-based R&D centre for inhalation products. GAVIS' New-Jersey based manufacturing facility will become Lupin's first manufacturing site in the US. GAVIS is a privately held company, specialising in formulation development, manufacturing, packaging, sales, marketing and distribution of pharmaceutical products. It has 62 abbreviated new drug application (ANDA) filings pending approval with the US FDA and a pipeline of over 65 plus products under development GAVIS' pending approvals address a market of over USD 9 billion. The combined company will have a portfolio of over 120 in-market products, more than 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest pipeline of ANDA filings with US FDA, catering to a USD 63.8-billion market. Lupin shares were trading 0.33 per cent up at Rs 1,822.75 during the afternoon session on BSE.
Drug major Lupin Announced completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS). Lupin had announced the acquisition on July 23, 2015. GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement its Florida-based R&D centre for inhalation products. GAVIS' New-Jersey based manufacturing facility will become Lupin's first manufacturing site in the US. GAVIS is a privately held company, specialising in formulation development, manufacturing, packaging, sales, marketing and distribution of pharmaceutical products. It has 62 abbreviated new drug application (ANDA) filings pending approval with the US FDA and a pipeline of over 65 plus products under development GAVIS' pending approvals address a market of over USD 9 billion. The combined company will have a portfolio of over 120 in-market products, more than 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest pipeline of ANDA filings with US FDA, catering to a USD 63.8-billion market. Lupin shares were trading 0.33 per cent up at Rs 1,822.75 during the afternoon session on BSE.

Monthly Current Affairs

Current Affairs Section

Daily Current Affairs Quiz

Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs 2018 September

18 SEPTEMBER
NEWS
17 SEPTEMBER
NEWS
16 SEPTEMBER
NEWS
15 SEPTEMBER
NEWS

Current Affairs 2018 August

31 AUGUST
NEWS
30 AUGUST
NEWS
29 AUGUST
NEWS
28 AUGUST
NEWS

Current Affairs 2018 July

31 JULY
NEWS
30 JULY
NEWS
29 JULY
NEWS
28 JULY
NEWS